title: Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen.
abstract: OBJECTIVE
  Treatment of thyroid cancer consists of thyroidectomy and radioiodine ablation following thyroid-stimulating hormone (TSH) stimulation. Similar ablation rates were obtained with either thyroid hormone withdrawal (THW) or rhTSH. But with rhTSH, the elimination of radioiodine is more rapid, thus reducing its whole-body retention and potentially resulting in a shorter hospital stay. The aim of this study was to assess the financial impact of a reduced length of hospital stay with the use of rhTSH.
  
  
  METHODS
  This was a case-control study of thyroid cancer patients treated postoperatively with 3,700 MBq (100 mCi) radioiodine; 35 patients who received rhTSH were matched with 64 patients submitted to THW according to covariates influencing radioiodine retention. The length of hospitalization (LOH) was estimated for each method according to the threshold of radioiodine retention below which the patient can be discharged from the hospital. The economic analysis was conducted from a hospital perspective. Simulations were performed.
  
  
  RESULTS
  For a threshold of 400 MBq, the LOH was 2.4 days and 3.5 days with rhTSH and THW, respectively, and the cost for an ablation stay was, respectively, 2,146 and 1,807 <euro>. In the French context, 57% of the acquisition cost of rhTSH was compensated by the reduction of the length of hospitalization.
  
  
  CONCLUSIONS
  By increasing the iodine excretion, rhTSH allows a shorter hospitalization length, which partially compensates its acquisition cost.
authors.affiliation: Detpartment of Health Economics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France. borget@igr.fr
authors.forename: I
authors.initials: I
authors.lastname: Borget
authors.forename: H
authors.initials: H
authors.lastname: Remy
authors.forename: J
authors.initials: J
authors.lastname: Chevalier
authors.forename: M
authors.initials: M
authors.lastname: Ricard
authors.forename: M
authors.initials: M
authors.lastname: Allyn
authors.forename: M
authors.initials: M
authors.lastname: Schlumberger
authors.forename: G
authors.initials: G
authors.lastname: De Pouvourville
mesh_terms: D016022:Case-Control Studies; D005260:Female; D005602:France / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007457:Iodine Radioisotopes / Q000191:economics* / Q000627:therapeutic use*; D007902:Length of Stay / Q000191:economics* / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D013964:Thyroid Neoplasms / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D013972:Thyrotropin / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin